All Oncology News

Here is your snapshot of all therapeutic options that the FDA approved in August 2024 and their clinical implications.

The FDA approved companion diagnostics for olaparib plus abiraterone in metastatic castration-resistant prostate cancer.

The phase 3 ELEMENT-MDS trial aims to expand access to luspatercept for anemia in non-transfusion dependent lower-risk MDS.

Sujith Samarasinghe, BSc, MBBS, MRCPCH, FRCPath, PhD, discusses the use of blinatumomab in children with Down syndrome acute lymphoblastic leukemia.

Eric Goodlev, MD, has joined Fox Chase Cancer Center as an associate Professor in the Supportive Oncology and Palliative Care Program.

Azercabtagene zapreleucel produced complete responses in relapsed/refractory diffuse large B-cell lymphoma after prior autologous CAR T-cell therapy.

The FDA has granted fast track designation to the allogeneic CAR T-cell therapy CB-012 for relapsed/refractory acute myeloid leukemia.

Debra Patt, MD, PhD, MBA, FASCO, details how the Medicare Drug Price Negotiation Program Draft Guidance will affect community oncologists and practices.

Mirdametinib showed a statistically significant ORR by BICR, with deep and durable tumor volume reductions in adults and children with NF1-PN.

Charlotte Lemech, MBBS, discusses the mechanism of action of MT-302, as well as the aims of the MYE Symphony trial and its potential future implications.

An international team of researchers led by Fox Chase Cancer Center evaluated practice patterns and the management of dermatofibrosarcoma protuberans.

Rahul Banerjee MD, FACP, discusses how he decides between treatment approaches across subsets of patients with multiple myeloma.

Arvind Dasari, MD, MS, discusses considerations and challenges associated with treating patients in the later-line colorectal cancer setting.

Mirdametinib NDA gets priority review in NF1-associated plexiform neurofibromas, experts explore social media's evolving role in cancer care, and more.

Jennifer R. Eads, MD, explains the relevance of negative results from the ECOG-ACRIN EA2174 trial in esophageal/gastroesophageal junction adenocarcinoma.

Bradley McGregor, MD, discusses how abemaciclib monotherapy did not elicit clinically meaningful activity in heavily pretreated metastatic clear cell RCC.

Encorafenib plus binimetinib has won approval from the European Commission for use in patients with BRAF V600E-mutated, advanced non–small lung cancer.

For more first-hand insights, head over to our YouTube channel to watch Dr Markman discuss the effects of information overload in oncology: https://rb.gy/bvumdn.

Third year in a row cancer center has been ranked on this listing, based on employee surveys.

The supplemental new drug application for fruquintinib plus paclitaxel in second-line gastric cancer in China has been voluntarily withdrawn.

The NuTide:323 trial of NUC-3373 plus leucovorin, irinotecan, and bevacizumab in second-line colorectal cancer has been discontinued.

In case you missed any, below is a recap of every OncLive On Air episode that aired in August 2024.

Alessandra Tedeschi, MD, discusses preliminary data from arm D of the SEQUOIA trial evaluating zanubrutinib plus venetoclax in high-risk, untreated CLL/SLL.

Courtney Van Houzen, PharmD, discusses key factors to be aware of when implementing bispecific T-cell engager programs into the community setting.

Consuelo Bertossi, MD, discusses research elucidating the role and prognostic significance of TP53 mutations in chronic lymphocytic leukemia.

Ankit Mangla, MD, expands on early data from the RELATIVITY-048 trial evaluating a triplet immunotherapy regimen in untreated advanced melanoma

Richard Bleicher, MD, FACS, Clinical Director of the Breast Service Line, has been promoted to Division Chief of Breast Surgery.

NXP800 was granted orphan drug designation by the FDA for the treatment of ARID1a-deficient ovarian, fallopian tube, and primary peritoneal cancers.

The phase 3 KEYNOTE-867 and KEYNOTE-630 trials evaluating pembrolizumab in NSCLC and CSCC, respectively, have been discontinued by Merck.